Background: Infection with the hepatitis C virus (HCV) causes acute hepatitis. This disease has a high probability of becoming chronic and leading to cirrhosis, but a more deadly consequence is hepatocellular carcinoma. Interferon α (IFNα)-based treatment combined with ribavirin is the major therapeutic choice available for the treatment of chronic HCV infection.
Aims: The scavenger receptor class B type I (SR-BI) or its human homologue CD36 and LIMPII Analogous-1 (hSR-BI/CLA-1) has recently been shown to interact with HCV envelope glycoprotein E2, thus suggesting that it might participate in entry of the virus into host cells. This rationale underlies current interest in the potential role of IFNα in hSR-BI/CLA-1 expression in HepG2 cells.
Results: It was shown that endogenous hepatocyte expression of hSR-BI/CLA-1 was suppressed by exposure to IFNα. Decreased hSR-BI/CLA-1 expression in IFNα-treated cells was due to lower transcriptional activity of the promoter. A potential pathway for the effect of IFNα on hSR-BI/CLA-1 promoter activity was identified when the inhibitory action of IFN was abrogated in signal transducer and activator of transcription 1 (STAT1)/STAT2 knocked-down cells. Exposure of HepG2 cells to IFNα elicited a rapid phosphorylation of STAT1/STAT2, a known target of IFNα signalling. In addition, the mutagenesis of a STAT1/STAT2 response element in the hSR-BI/CLA-1 promoter abolished the ability of IFNα to suppress promoter activity.
Conclusions: Together, these results indicate that the STAT1/STAT2 pathway participates in IFNα inhibtion of hSR-BI/CLA-1 expression, and raise the possibility that lowering the expression of this gene may be of therapeutic value for treating HCV infections.
Statistics from Altmetric.com
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.